Copyright
©The Author(s) 2021.
World J Meta-Anal. Dec 28, 2021; 9(6): 522-542
Published online Dec 28, 2021. doi: 10.13105/wjma.v9.i6.522
Published online Dec 28, 2021. doi: 10.13105/wjma.v9.i6.522
Table 2 Strategies for cytomegalovirus prevention in liver transplant patients based on risk status
| Risk status | Donor/Recipient CMV serological status | Prevention strategy |
| High risk | Donor positive/recipient negative | Prophylactic therapy for 3-6 mo |
| Or | ||
| Pre-emptive therapy requiring close monitoring | ||
| Intermediate risk | Donor positive/recipient positive | Prophylactic therapy for 3 mo |
| Or | ||
| Pre-emptive therapy requiring close monitoring | ||
| Intermediate risk | Donor negative/recipient positive | Prophylactic therapy for 3 mo |
| Or | ||
| Pre-emptive therapy requiring close monitoring | ||
| Low risk | Donor negative/recipient negative | No routing prophylaxis |
- Citation: Gupta M, Manek G, Dombrowski K, Maiwall R. Newer developments in viral hepatitis: Looking beyond hepatotropic viruses. World J Meta-Anal 2021; 9(6): 522-542
- URL: https://www.wjgnet.com/2308-3840/full/v9/i6/522.htm
- DOI: https://dx.doi.org/10.13105/wjma.v9.i6.522